GBT could be valued at $4.5 billion to $5.5 billion in a takeover, William Blair analyst Raju Prasad said in a note. GBT is primarily focused on the sickle cell disease market which has begun to experience increased competition. The company, which also has operations in Switzerland, France, Germany and the UK, had a net loss of $303 million on revenue of $195 million last year.
...more